Please assess the completion status of the following clinical trial:

Trial Title: Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy volunteers, 18-50 years of age~* Seronegative for H5N1 (with antibody titres \<1:10 detected in HAI assay)~* Seronegative for H1N1 (with antibody titres ≤1:20 detected in HAI assay)~* Written informed consent to participate in this study~Exclusion Criteria:~* Acute febrile illness (\>37.0°C)~* Positive influenza immunoassay at baseline~* Signs of acute or chronic upper or lower respiratory tract illnesses (sneezing, cough, tonsillitis, otitis, etc.)~* History of severe atopy~* Influenza vaccination 2006/2007 and/or later~* Known increased tendency of nose bleeding~* Volunteers with clinically relevant abnormal paranasal anatomy~* Volunteers with clinically relevant abnormal laboratory values Females with positive urine pregnancy test prior to vaccination~* Simultaneous treatment with immunosuppressive drugs incl. corticosteroids (≥ 2 weeks) within 4 weeks prior to study medication application~* Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases~* History of leukaemia or cancer~* HIV or hepatitis B or C seropositivity~* Volunteers who had undergone rhino or sinus surgery or surgery of another traumatic injury of the nose within 30 days prior to application of study medication~* Volunteers who had received antiviral drugs, treatment with immunoglobulins or blood transfusions or an investigational drug within four weeks prior to study medication application~* Volunteers who had received anti-inflammatory drugs 2 days prior to study medication application~* Volunteers who were not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- GHB04L1 (Type: EXPERIMENTAL): GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.

Based on this trial design, predict the completion outcome and termination type (if applicable).